In a bid to rework the controversial relationship between drugmakers and patient charities, Regeneron Pharmaceuticals has announced a new program in which it will match up to $200 million in donations this year to a leading foundation called Good Days.
The move comes after Regeneron several months ago slashed its funding to the charity, an unexpected step that appeared largely designed to blunt the use of eye medicines sold by rivals, but one that has reduced patient access and, in turn, sparked concern among investors and physicians.
Indeed, that decision has slowed the company’s revenue growth and has prompted some ophthalmologists to complain their patients have been losing access to needed treatments. The American Society of Retinal Specialists, for instance, issued patient bulletins and held online sessions for doctors seeking to help patients afford injectable medicines to combat macular degeneration and other eye diseases.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
